Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Time to Buy?

by · The Markets Daily

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $21.20, but opened at $21.92. Chugai Pharmaceutical shares last traded at $21.5112, with a volume of 1,627 shares traded.

Analysts Set New Price Targets

CHGCY has been the topic of a number of recent research reports. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group cut shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

View Our Latest Stock Report on CHGCY

Chugai Pharmaceutical Trading Up 1.3%

The firm has a 50 day moving average price of $20.76 and a 200-day moving average price of $22.85. The firm has a market capitalization of $71.82 billion, a P/E ratio of 23.72 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last posted its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.

Read More